Compare Abeona Therapeutics Inc (ABEO) vs iShares MSCI Australia ETF (EWA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares MSCI Australia ETF — how do they compare? Abeona Therapeutics Inc trades at $6.77 (market cap $373.32M), while iShares MSCI Australia ETF trades at $28.08. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares MSCI Australia ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | EWA | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $7.23 | $30.26 |
52-Week Low | $4.17 | $24.95 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
EWA trades at $28.33, up 0.85% on the day, with technical indicators showing a bearish trend in moving averages and mixed signals from oscillators. The stock faces resistance near $29 and support at $28. Recent news highlights Australian economic headwinds, including missed GDP growth and regulatory changes affecting banks and property markets, which may influence EWA's performance given its exposure to Australian equities.
The outlook for EWA is cautious due to bearish technicals and macroeconomic pressures in Australia. Risks include slower economic growth and sector-specific challenges, but potential opportunities exist if market sentiment improves or if dividend policies attract income-focused investors. Investors should weigh these factors against the current neutral-to-bearish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →
